1. Iloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure. Results of a randomized pilot study

   • K. Spargias
   • E. Adreanides
   • D. V. Cokkinos

   Clinical Trials 11 July 2006 Pages: 589 - 595

   

2. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes

   • Mikiko Shimizu
   • Tsukasa Uno
   • Tomonori Tateishi

   Clinical Trials 17 June 2006 Pages: 597 - 603

   

3. Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients

   • Giovanni Tarantino
   • Paolo Conca
   • Vincenzo Basile

   Pharmacodynamics 14 July 2006 Pages: 605 - 612

   

4. Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study

   • Dagmar Busse
   • Silke Templin
   • Kari T. Kivistö

   Pharmacodynamics 04 July 2006 Pages: 613 - 619

   

5. Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4

   • Ylva Böttiger

   Pharmacogenetics 22 June 2006 Pages: 621 - 625

   

6. Associations between CYP2E1 promoter polymorphisms and plasma 1,3-dimethyluric acid/theophylline ratios

   • Yeomin Yoon
   • Hyung-Doo Park
   • Junghan Song

   Pharmacogenetics 14 July 2006 Pages: 627 - 631

   

7. Transfer of reboxetine into breastmilk, its plasma concentrations and lack of adverse effects in the breastfed infant

   • L. Peter Hackett
   • Kenneth F. Ilett
   • Rolland Kohan

   Pharmacokinetics and Disposition 13 May 2006 Pages: 633 - 638

   

8. Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes

   • Stephanie Bomsien
   • Rolf Aderjan
   • Gisela Skopp

   Pharmacokinetics and Disposition 27 June 2006 Pages: 639 - 643

   

9. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone

   • Aleksi Tornio
   • Pertti J. Neuvonen
   • Janne T. Backman

   Pharmacokinetics and Disposition 11 July 2006 Pages: 645 - 651

   

10. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers

    • Emmanuel Krupka
    • Nicolas Venisse
    • Marie-Christine Perault

    Pharmacokinetics and Disposition 11 July 2006 Pages: 653 - 659

    

11. Use of an online surveillance system for screening drug interactions in prescriptions in community pharmacies

    • Tiina Heikkilä
    • Tuula Lekander
    • Hannu Raunio

    Pharmacoepidemiology and Prescription 22 June 2006 Pages: 661 - 665

12. Patterns and utilization of isotretinoin for acne from 1984 to 2003: is there need for concern?

    • Laurent Azoulay
    • Driss Oraichi
    • Anick Bérard

    Pharmacoepidemiological and Prescription 22 June 2006 Pages: 667 - 674

13. Correlation of drug utilisation and morbidity at the municipality level. High use of antibiotics associated with low use of antihypertensives

    • J. Lars G. Nilsson
    • Gunnar Lindberg
    • Arne Melander

    Pharmacoepidemiology and Prescription 06 July 2006 Pages: 675 - 680

14. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers

    • M. Joerger
    • T. M. Bosch
    • J. H. M. Schellens

    Short Communication 24 June 2006 Pages: 681 - 684